IgM-enriched Human Intravenous Immunoglobulin Suppresses T Lymphocyte Functions in Vitro and Delays the Activation of T Lymphocytes in Hu-SCID Mice

Overview

Journal Clin Exp Immunol

Publisher Oxford University Press

Specialty Allergy & Immunology

Date 2006 Jun 24

PMID 16792680

Citations 7

Authors

T Vassilev

N Mihaylova

E Voynova

M Nikolova

M Kazatchkine

S Kaveri

Affiliations

Soon will be listed here.

Abstract

Previous studies of an experimental human immunoglobulin preparation for intravenous use, containing normal pooled IgM (IVIgM), have shown its beneficial therapeutic effect in experimental autoimmune diseases. The mechanisms of its immunomodulatory activity remain however, poorly understood. In the experiments reported here, IVIgM inhibited the proliferation of various autonomously growing human lymphoid cell lines in vitro, as well as of MLR- and of PHA-stimulated human T-lymphocytes. These effects of IVIgM were observed at non-apoptotic concentrations and were stronger on a molar basis than those of normal pooled IgG for intravenous use (IVIg). Both preparations, when administered to SCID mice, repopulated with human peripheral blood mononuclear cells, delayed the expression of the early activation marker CD69 on both human CD4+ and CD8+ T-lymphocytes, activated by the mouse antigenic environment. The data obtained show that normal pooled human IgM exerts a powerful antiproliferative effect on T-cells that is qualitatively similar but quantitatively superior to that of therapeutic IVIg. Our results suggest that infusions with IVIgM might have a significant beneficial immunomodulating activity in patients with selected autoimmune diseases.

Citing Articles

The use of high-dose immunoglobulin M-enriched human immunoglobulin in dogs with immune-mediated hemolytic anemia.

Bestwick J, Sharman M, Whitley N, Kisielewicz C, Skelly B, Tappin S J Vet Intern Med. 2021; 36(1):78-85.

PMID: 34779044 PMC: 8783326. DOI: 10.1111/jvim.16315.

Characteristics of Immunoglobulin M Type Antibodies of Different Origins from the Immunologic and Clinical Viewpoints and Their Application in Controlling Antibody-Mediated Allograft Rejection.

Matsuda Y, Hiramitsu T, Li X, Watanabe T Pathogens. 2020; 10(1).

PMID: 33374617 PMC: 7822424. DOI: 10.3390/pathogens10010004.

Role of Natural Autoantibodies and Natural IgM Anti-Leucocyte Autoantibodies in Health and Disease.

Lobo P Front Immunol. 2016; 7:198.

PMID: 27375614 PMC: 4893492. DOI: 10.3389/fimmu.2016.00198.

Natural IgM in immune equilibrium and harnessing their therapeutic potential.

Kaveri S, Silverman G, Bayry J J Immunol. 2012; 188(3):939-45.

PMID: 22262757 PMC: 3266110. DOI: 10.4049/jimmunol.1102107.

Natural IgM anti-leukocyte autoantibodies attenuate excess inflammation mediated by innate and adaptive immune mechanisms involving Th-17.

Lobo P, Bajwa A, Schlegel K, Vengal J, Lee S, Huang L J Immunol. 2012; 188(4):1675-85.

PMID: 22262657 PMC: 3273570. DOI: 10.4049/jimmunol.1101762.

References

Prasad N, Papoff G, Zeuner A, Bonnin E, Kazatchkine M, Ruberti G . Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol. 1998; 161(7):3781-90. View

Nachbaur D, Herold M, Gachter A, Niederwieser D . Modulation of alloimmune response in vitro by an IgM-enriched immunoglobulin preparation (Pentaglobin). Immunology. 1998; 94(2):279-83. PMC: 1364217. DOI: 10.1046/j.1365-2567.1998.00495.x. View

Rieben R, Roos A, Muizert Y, Tinguely C, Gerritsen A, Daha M . Immunoglobulin M-enriched human intravenous immunoglobulin prevents complement activation in vitro and in vivo in a rat model of acute inflammation. Blood. 1999; 93(3):942-51. View

Jonsson V, Wiik A, HOU-JENSEN K, Christiansen M, Ryder L, Madsen H . Autoimmunity and extranodal lymphocytic infiltrates in lymphoproliferative disorders. J Intern Med. 1999; 245(3):277-86. DOI: 10.1046/j.1365-2796.1999.0443f.x. View

Zander A, Zabelina T, Kroger N, Renges H, Kruger W, Loliger C . Use of a five-agent GVHD prevention regimen in recipients of unrelated donor marrow. Bone Marrow Transplant. 1999; 23(9):889-93. DOI: 10.1038/sj.bmt.1701745. View

Jonsson V, Kierkegaard A, Salling S, Molander S, Andersen L, Christiansen M . Autoimmunity in Waldenström's macroglobulinaemia. Leuk Lymphoma. 1999; 34(3-4):373-9. DOI: 10.3109/10428199909050962. View

Kress H, Scheidewig C, Schmidt H, Silber R . Reduced incidence of postoperative infection after intravenous administration of an immunoglobulin A- and immunoglobulin M-enriched preparation in anergic patients undergoing cardiac surgery. Crit Care Med. 1999; 27(7):1281-7. DOI: 10.1097/00003246-199907000-00011. View

David K, Ollert M, Vollmert C, Heiligtag S, Eickhoff B, Erttmann R . Human natural immunoglobulin M antibodies induce apoptosis of human neuroblastoma cells by binding to a Mr 260,000 antigen. Cancer Res. 1999; 59(15):3768-75. View

Vassilev T, Yamamoto M, Aissaoui A, Bonnin E, Berrih-Aknin S, Kazatchkine M . Normal human immunoglobulin suppresses experimental myasthenia gravis in SCID mice. Eur J Immunol. 1999; 29(8):2436-42. DOI: 10.1002/(SICI)1521-4141(199908)29:08<2436::AID-IMMU2436>3.0.CO;2-9. View

10.

Stahl D, Lacroix-Desmazes S, Heudes D, Mouthon L, Kaveri S, Kazatchkine M . Altered control of self-reactive IgG by autologous IgM in patients with warm autoimmune hemolytic anemia. Blood. 1999; 95(1):328-35. View

11.

Boes M, Schmidt T, Linkemann K, Beaudette B, Marshak-Rothstein A, Chen J . Accelerated development of IgG autoantibodies and autoimmune disease in the absence of secreted IgM. Proc Natl Acad Sci U S A. 2000; 97(3):1184-9. PMC: 15562. DOI: 10.1073/pnas.97.3.1184. View

12.

Bar-Dayan Y, Bonnin E, Bloch M, Schweitzer R, Ravid M, Kazatchkine M . Neutralization of disease associated autoantibodies by an immunoglobulin M- and immunoglobulin A-enriched human intravenous immunoglobulin preparation. Scand J Immunol. 2000; 51(4):408-14. DOI: 10.1046/j.1365-3083.2000.00699.x. View

13.

Ehrenstein M, Cook H, Neuberger M . Deficiency in serum immunoglobulin (Ig)M predisposes to development of IgG autoantibodies. J Exp Med. 2000; 191(7):1253-8. PMC: 2193170. DOI: 10.1084/jem.191.7.1253. View

14.

Lissner R, Struff W, Autenrieth I, Woodcock B, Karch H . Efficacy and potential clinical applications of Pentaglobin, an IgM-enriched immunoglobulin concentrate suitable for intravenous infusion. Eur J Surg Suppl. 2000; (584):17-25. DOI: 10.1080/11024159950188493. View

15.

Patel S, Han J, Arakelov S, Rao T, Shulman M, Fazel S . The IgA/IgM receptor expressed on a murine B cell lymphoma is poly-Ig receptor. J Immunol. 2000; 165(5):2544-55. DOI: 10.4049/jimmunol.165.5.2544. View

16.

Bieber A, Asakura K, Warrington A, Kaveri S, Rodriguez M . Antibody-mediated remyelination: relevance to multiple sclerosis. Mult Scler. 2001; 6 Suppl 2:S1-5; discussion S33. View

17.

Samuelsson A, Towers T, Ravetch J . Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science. 2001; 291(5503):484-6. DOI: 10.1126/science.291.5503.484. View

18.

Marches R, Vitetta E, UHR J . A role for intracellular pH in membrane IgM-mediated cell death of human B lymphomas. Proc Natl Acad Sci U S A. 2001; 98(6):3434-9. PMC: 30671. DOI: 10.1073/pnas.061028998. View

19.

Shibuya A, Sakamoto N, Shimizu Y, Shibuya K, Osawa M, Hiroyama T . Fc alpha/mu receptor mediates endocytosis of IgM-coated microbes. Nat Immunol. 2001; 1(5):441-6. DOI: 10.1038/80886. View

20.

Owen R, Lubenko A, Savage J, Parapia L, Jack A, Morgan G . Autoimmune thrombocytopenia in Waldenström's macroglobulinemia. Am J Hematol. 2001; 66(2):116-9. DOI: 10.1002/1096-8652(200102)66:2<116::AID-AJH1026>3.0.CO;2-V. View